Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
NCT02181790 · Icahn School of Medicine at Mount Sinai · PHASE4 · terminated · last registry update 2021-03-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of subjects” | – | Registry record, Icahn School of Medicine at Mount Sinai |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RXRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-16Results posted on the registry: Novartis Pharmaceuticals, Panobinostat (NCT00425555)
- 2021-06-30Results posted on the registry: University of Washington, Gene Expression Analysis + Genetic Variation Analysis (NCT02551718)
- 2021-05-14Results posted on the registry: Io Therapeutics, NRX 194204 (NCT01540071)
- 2020-12-17Also stopped (terminated): Abramson Cancer Center at Penn Medicine, Bexarotene (NCT00615784)
- 2020-11-17Results posted on the registry: Abramson Cancer Center at Penn Medicine, Bexarotene (NCT00615784)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision